Oxford Immunotec Global 10-Q 5 Nov 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Oxford Immunotec Global PLC	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	17,611,348
Amendment Flag	'false	'
Entity Central Index Key	'0001586049	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets	'	'
Cash and cash equivalents	$58,007	$76,494
Restricted cash	146	87
Accounts receivable, net	5,211	4,754
Inventory	6,515	5,450
Prepaid expenses and other	2,155	2,242
Total current assets	72,034	89,027
Restricted cash, non-current	246	362
Property and equipment, net	4,463	2,964
In-process research and development	2,497	'
Goodwill	55	'
Other intangible assets, net	295	331
Other assets	26	60
Total assets	79,616	92,744
Liabilities and shareholders’ equity	'	'
Accounts payable	2,901	2,310
Accrued liabilities	6,177	6,936
Deferred income	1,699	1,540
Current portion of loans payable	170	170
Taxes payable	'	177
Total current liabilities	10,947	11,133
Long-term portion of loans payable	449	563
Contingent purchase price consideration	1,234	'
Other liabilities	'	296
Total liabilities	12,630	11,992
Shareholders’ equity:	'	'
Ordinary shares, £0.006705 nominal value; 40,103,528 and 25,189,285 shares authorized at September 30, 2014 and December 31, 2013, respectively, and 17,611,348 and 17,255,267 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	192	188
Additional paid-in capital	186,053	183,967
Accumulated deficit	-115,137	-99,655
Accumulated other comprehensive loss	-4,122	-3,748
Total shareholders’ equity	66,986	80,752
Total liabilities and shareholders’ equity	$79,616	$92,744

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (GBP £)	Sep. 30, 2014	Dec. 31, 2013
Ordinary shares, nominal value (in Pounds per share)	£ 0.006705	£ 0.006705
Ordinary shares, shares authorized	40,103,528	25,189,285
Ordinary shares, shares issued	17,611,348	17,255,267
Ordinary shares, shares outstanding	17,611,348	17,255,267

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue:	'	'	'	'
Product	$6,480	$4,977	$19,192	$14,888
Service	6,845	5,749	18,195	13,671
Total revenue	13,325	10,726	37,387	28,559
Cost of revenue:	'	'	'	'
Product	2,944	2,158	8,807	6,767
Service	3,568	2,773	9,710	7,398
Total cost of revenue	6,512	4,931	18,517	14,165
Gross profit	6,813	5,795	18,870	14,394
Operating expenses:	'	'	'	'
Research and development	1,946	579	4,185	1,583
Sales and marketing	7,468	3,325	18,376	9,557
General and administrative	3,567	4,084	11,447	8,457
Total operating expenses	12,981	7,988	34,008	19,597
Loss from operations	-6,168	-2,193	-15,138	-5,203
Other (expense) income:	'	'	'	'
Interest expense, net	-41	-139	-104	-256
Foreign exchange gains (losses)	76	-721	-331	44
Other income (expense)	91	-113	170	114
Loss before income taxes	-6,042	-3,166	-15,403	-5,301
Income tax expense	53	15	79	35
Net loss	($6,095)	($3,181)	($15,482)	($5,336)
Net loss per share attributable to ordinary shareholders—basic and diluted (in Dollars per share)	($0.35)	($1.36)	($0.89)	($2.36)
Weighted-average shares used to compute net loss attributable to ordinary shareholders—basic and diluted (in Shares)	17,333,441	2,331,990	17,300,881	2,256,494

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Other Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net loss	($6,095)	($3,181)	($15,482)	($5,336)
Other comprehensive income (loss), net of taxes:	'	'	'	'
Foreign currency translation adjustment, net of taxes	-672	614	-374	-447
Other comprehensive income (loss), net of taxes	-672	614	-374	-447
Total comprehensive loss	($6,767)	($2,567)	($15,856)	($5,783)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities	'	'
Net loss	($15,482)	($5,336)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	1,239	863
Share-based compensation expense	1,759	77
Loss on change in fair value of warrants	22	119
Loss on disposal of property and equipment	'	-1
Changes in operating assets and liabilities, net of acquisitions:	'	'
Accounts receivable, net	-480	-1,788
Inventory	-1,112	-1,389
Prepaid expenses and other	115	-2,445
Accounts payable	290	1,732
Accrued liabilities	-713	1,242
Deferred income	191	1,196
Net cash used in operating activities	-14,171	-5,730
Cash flows from investing activities	'	'
Purchases of property and equipment	-2,567	-1,542
Purchases of intangible assets	-17	'
Cash paid for acquisition, net of cash acquired	-1,716	'
Proceeds on sales of property and equipment	'	22
Decrease in restricted cash	57	225
Net cash used in investing activities	-4,243	-1,295
Cash flows from financing activities	'	'
Proceeds from issuance of preferred ordinary shares	'	2,942
Proceeds from exercise of share options and warrants	13	17
Proceeds from term loan	'	6,000
Payments on loan	-139	-60
Payments on revolving line of credit	'	-1,500
Net cash (used in) provided by financing activities	-126	7,399
Effect of exchange rate changes on cash and cash equivalents	53	83
Net (decrease) increase in cash and cash equivalents, excluding restricted cash	-18,487	457
Cash and cash equivalents at beginning of period	76,494	12,578
Cash and cash equivalents at end of period	58,007	13,035
Noncash investing and financing activities:	'	'
Fair value of warrant issued with convertible notes	'	136
Warrants liability reclassified to additional paid-in capital upon exercise of warrants	$318	'

Note_1_Business_and_Basis_of_P

Note 1 - Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Basis of Presentation and Significant Accounting Policies [Text Block]	'
	1. Business and basis of presentation
	Description of business
	Oxford Immunotec Global PLC (the “Company”), is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. The Company’s proprietary T-SPOT® technology platform allows it to measure the responses of specific immune cells (T cells) to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. Substantially all of the Company’s revenue is currently derived from the sale of its T-SPOT.TB test, which is sold in two formats: an in vitro diagnostic kit format (allowing customers to perform the test at their own institutions), and a service format (in which the Company performs the test on samples sent by customers to the Company’s own laboratory facilities). The Company sells its T-SPOT.TB test through a direct sales force in the United States, certain European countries and Japan. The Company sells through distributors in other parts of the world.
	On July 31, 2014, the Company acquired substantially all of the assets of Boulder Diagnostics, Inc. (“Boulder”), a privately owned company developing immunology-based assays for rheumatology and infectious diseases. The assets acquired primarily relate to assays for Lyme disease and gout and an assay to help select biologics for autoimmune disease based on monitoring and prognosis of drug response that was acquired in conjunction with the Boulder acquisition. This acquisition brought the Company three additional early-stage pipeline opportunities, using complementary immune-measuring technology. Each opportunity has the potential to address key unmet clinical needs and is well suited to the Company’s growing commercial infrastructure.
	Unaudited Interim Financial Statements
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the interim consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at September 30, 2014, the results of operations for the three and nine-month periods ended September 30, 2014 and 2013, and the cash flows for the nine-month periods ended September 30, 2014 and 2013. Interim results are not necessarily indicative of results for a full year.
	The consolidated balance sheet presented as of December 31, 2013, has been derived from the audited consolidated financial statements as of that date. The consolidated financial statements and notes included in this report should be read in conjunction with the 2013 consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 27, 2014 (the “Company’s 2013 Form 10-K”).
	Note 1 to the consolidated financial statements included in the Company’s 2013 Form 10-K describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. The accounting for restricted shares, which were issued by the Company for the first time during the three months ended March 31, 2014, is described in Note 6. In conjunction with the acquisition of Boulder on July 31, 2014 (see Note 9), the Company has adopted the significant accounting policies listed below.
	Business Combinations
	For acquisitions meeting the definition of a business combination, the Company allocates the purchase price, including any contingent consideration, to the assets acquired and the liabilities assumed at their estimated fair values as of the date of the acquisition with any excess of the purchase price paid over the estimated fair value of net assets acquired recorded as goodwill. The fair value of the assets acquired and liabilities assumed is typically determined by using either estimates of replacement costs or discounted cash flow valuation methods.
	When determining the fair value of tangible assets acquired, the Company estimates the cost using the most appropriate valuation method with assistance from independent third party specialists. When determining the fair value of intangible assets acquired, the Company uses judgment to estimate the applicable discount rate, growth rates and the timing and amount of future cash flows. The fair value of assets acquired and liabilities assumed is typically determined by management using the assistance of independent third party specialists. The assumptions used in calculating the fair value of tangible and intangible assets represent the Company’s best estimates and involve inherent uncertainties and the application of its judgment. As a result, if factors change and the Company uses different assumptions, valuations of tangible and intangible assets and the resulting goodwill balance related to the business combination could be materially different or impaired in the future.
	Goodwill and Indefinite-lived Intangible Assets
	Goodwill
	Goodwill is not amortized but is reviewed for impairment at least annually, or when events or changes in the business environment indicate that all, or a portion, of the carrying value of the reporting unit may no longer be recoverable, using the two-step impairment review. Under this method, the Company compares the fair value of the goodwill to its carrying value. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine if goodwill is impaired. An impairment loss, if any, is measured as the excess of the carrying value of goodwill over the fair value of goodwill. The Company also has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads it to determine that it is more likely than not (that is, a likelihood of more than 50%) that goodwill is impaired. If the Company chooses to first assess qualitative factors and it is determined that it is not more likely than not goodwill is impaired, it is not required to take further action to test for impairment. The Company also has the option to bypass the qualitative assessment and perform only the quantitative impairment test, which it may choose to do in some periods but not in others.
	Indefinite-lived Intangible Assets
	The Company’s indefinite-lived intangible assets consist of acquired in-process research and development (“IPR&D”), related to the Company’s business combination with Boulder, which were recorded at fair value on the acquisition date. IPR&D intangible assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not amortized but is reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may be impaired. If the fair value of the intangible asset is less than the carrying amount, the Company performs a quantitative test to determine the fair value. The impairment loss, if any, is measured as the excess of the carrying value of the intangible asset over its fair value. The Company also has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads it to determine that it is more likely than not (that is, a likelihood of more than 50%) that its indefinite-lived intangible asset is impaired. If the Company chooses to first assess qualitative factors and it is determined that it is not more likely than not our indefinite-lived intangible asset is impaired, it is not required to take further action to test for impairment. The Company also has the option to bypass the qualitative assessment and perform only the quantitative impairment test, which it may choose to do in some periods but not in others.
	The determinations as to whether, and, if so, the extent to which, acquired IPR&D become impaired are highly judgmental and based on significant assumptions regarding the projected future financial condition and operating results, changes in the manner of the use and development of the acquired assets, the Company’s overall business strategy, and regulatory, market and economic environment and trends.
	Recent accounting pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”), issued Accounting Standards Update, or ASU, 2014-09, Revenue from Contracts with Customers, which converges the FASB and the International Accounting Standards Board standard on revenue recognition. Under ASU 2014-09, a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This guidance will be effective for the Company for annual and interim periods beginning after December 15, 2016. Early adoption is not permitted. The guidance allows for either “full retrospective” adoption, meaning the standard is applied to all of the periods presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements. The Company is currently evaluating ASU 2014-09 and has not yet determined how it may impact the Company’s financial position or results of operations and related disclosures.
	In August 2014 the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern, or ASU 2014-15. ASU 2014-15 will be effective for fiscal years and interim periods beginning after December 15, 2016 and early application is permitted. ASU 2014-15 requires that management evaluate at each annual and interim reporting period whether there is a substantial doubt about an entity’s ability to continue as a going concern within one year of the date that the financial statements are issued. The Company does not expect that the application of ASU 2014-15 will have an impact on the presentation of our results of operations, financial position or disclosures.

Note_2_Fair_Value_Measurement

Note 2 - Fair Value Measurement	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	2. Fair value measurement
	As a basis for determining the fair value of certain of the Company’s financial instruments, the Company utilizes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level I—Observable inputs such as quoted prices in active markets for identical assets or liabilities.
	Level II—Observable inputs, other than Level I prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level III—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The carrying amount of certain of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses and other assets, accounts payable, and accrued liabilities approximate fair value due to their short maturities.
	Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability.
	The following tables present information about the balances of liabilities measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques it utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates, and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. The Company did not have any financial assets measured at fair value on a recurring basis.
					Fair value measurements at September 30, 2014 using
	(in thousands)	30-Sep-14			Quoted prices in active markets for identical assets		Significant		Significant
					(Level 1)		other		unobservable
							observable		inputs
							inputs		(Level 3)
							(Level 2)
	Liabilities:
	Contingent purchase price consideration	$	1,234		$	—	$	—	$	1,234
	Total	$	1,234		$	—	$	—	$	1,234
					Fair value measurements at December 31, 2013 using
	(in thousands)	31-Dec-13			Quoted prices in active markets for identical assets		Significant		Significant
					(Level 1)		other		unobservable
							observable		inputs
							inputs		(Level 3)
							(Level 2)
	Liabilities:
	Ordinary share warrants	$	296		$	—	$	—	$	296
	Total	$	296		$	—	$	—	$	296
	In May 2013, the Company entered into a loan and security agreement with Square 1 Bank that provided for an initial borrowing of $6.0 million and, subject to the achievement of certain revenue milestones, the ability to borrow an additional $1.0 million in January 2014. The Company also received access to a $5.0 million revolving line of credit. The Company concurrently issued a warrant to purchase up to 15,791 ordinary shares of the Company at an exercise price of $0.80 per share. Due to the lack of market quotes relating to the Company’s ordinary share warrants, the fair value of the warrants was determined using the Black-Scholes model, which is based on Level 3 inputs. In December 2013, the Company repaid the loan in full and canceled the line of credit.
	In April 2014, Square 1 Bank converted its warrant and received 15,148 ordinary shares of the Company, in accordance with a formula stated in the warrant agreement. Prior to the warrant conversion, the fair value of the warrant was adjusted to its fair value at the date of exercise of $318,000, with the loss on change in fair value recorded in the statement of operations. The liability for the warrant on conversion was then reclassified to additional paid-in capital.
	On July 31, 2014, the Company acquired substantially all of the assets of Boulder, a privately owned company developing immunology-based assays for rheumatology and infectious diseases. The terms of the purchase agreement included contingent purchase price consideration consisting of future potential milestone payments totaling up to $6.1 million at any time on or prior to July 31, 2024. The milestone payments consist of completion of studies related to acquired technologies, development of diagnostic test kits, patient enrollment in an Institutional Review Board approved study, issuance of patents, and approvals or clearances by the U.S. Food and Drug Administration. The fair value of future potential milestone payments was determined based upon a probability weighted analysis of expected future milestone payments to be made to the seller, which are considered as Level 3 inputs.
	The following tables provide a summary of changes in the fair value of the Company's Level 3 liabilities for the three and nine-month periods ended September 30, 2014:
	(in thousands)	Three months ended September 30, 2014
	Balance – beginning	$	—
	Contingent purchase price consideration		1,247
	Change in fair value of contingent purchase price consideration		38
	Foreign currency adjustment		(51	)
	Balance at September 30, 2014	$	1,234
	(in thousands)	Nine months ended September 30, 2014
	Balance – beginning	$	296
	Change in fair value of warrant liability		22
	Reclassification of liability to additional paid-in capital upon exercise of warrants		(318	)
	Contingent purchase price consideration		1,247
	Change in fair value of contingent purchase price consideration		38
	Foreign currency adjustment		(51	)
	Balance at September 30, 2014	$	1,234

Note_3_Accounts_Receivable_Net

Note 3 - Accounts Receivable, Net	9 Months Ended
	Sep. 30, 2014
Receivables [Abstract]	'
Financing Receivables [Text Block]	'
	3. Accounts receivable, net
	Accounts receivable, net, consisted of the following as of:
	(in thousands)	September 30,			December 31,
		2014			2013
	Accounts receivable	$	5,325		$	4,919
	Less allowance for uncollectible accounts receivable		(114	)		(165	)
	Accounts receivable, net	$	5,211		$	4,754

Note_4_Inventory

Note 4 - Inventory	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	4. Inventory
	Inventory consisted of the following as of:
	(in thousands)	September 30,		December 31,
		2014		2013
	Raw materials	$	3,455	$	2,866
	Finished goods		3,060		2,584
	Inventory, net	$	6,515	$	5,450

Note_5_Accrued_Liabilities

Note 5 - Accrued Liabilities	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	5. Accrued liabilities
	Accrued liabilities consisted of the following as of:
	(in thousands)	September 30,		December 31,
		2014		2013
	Employee related expenses	$	3,278	$	2,766
	Royalties		1,390		2,064
	Professional services		433		99
	Rent		256		366
	Inventory		136		293
	Accrued initial public offering costs		—		845
	Other accrued liabilities		684		503
	Total accrued liabilities	$	6,177	$	6,936

Note_6_Share_Option_and_Equity

Note 6 - Share Option and Equity Incentive Plan	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	6. Share option and equity incentive plan
	Expense recognized related to share-based compensation was as follows:
		Three months ended September 30,				Nine months ended September 30,
	(in thousands)	2014		2013		2014		2013
	Cost of revenue	$	37	$	1	$	91	$	3
	General and administrative		435		51		1,045		68
	Research and development		20		—		30		—
	Sales and marketing		242		—		593		6
	Total share-based compensation	$	734	$	52	$	1,759	$	77
	In November 2013, in connection with the Company’s initial public offering, the Company adopted the 2013 Share Incentive Plan (the “2013 Plan”), which provides for the grant of share options, restricted shares, RSUs and other share-based awards to employees, officers, directors and consultants of the Company.
	During the three-month period ended September 30, 2014, the Company granted to certain employees 89,800 share options with an exercise price of $13.25 per share under the 2013 Plan. The weighted-average grant date fair value related to share options granted under the 2013 Plan during the three-month period ended September 30, 2014 was $6.28 per share. During the nine-month period ended September 30, 2014, the Company granted to certain employees 556,252 share options with exercise prices ranging from $13.25 to $22.99 per share under the 2013 Plan. The weighted-average grant date fair value related to share options granted under the 2013 Plan during the nine-month period ended September 30, 2014 was $9.71 per share. Share options generally vest based on the grantee’s continued service with the Company during a specified period following the vesting start date or, in rare instances, based on the achievement of performance or other conditions as determined by the Board of Directors, and expire after ten years.
	During the three months ended September 30, 2014, the Company awarded an employee 20,800 restricted shares with a grant date fair value equal to $13.25 per share under the 2013 Plan. During the nine months ended September 30, 2014, the Company awarded certain employees 275,500 restricted shares with a weighted average grant date fair value equal to $22.25 per share under the 2013 Plan. The restricted shares vest based on the grantee’s continued service with the Company during a specified period following grant as follows: 40% on the second anniversary of the grant date; 30% on the third anniversary of the grant date; and 30% on the fourth anniversary of the grant date. Share-based compensation expense for these restricted shares is calculated based on the grant date market price of the shares and is being recognized over the vesting period.
	For the three-month period ended September 30, 2014, the Company incurred shared-based compensation expense related to share options and restricted shares of $446,000 and $288,000, respectively. For the three-month period ended September 30, 2013, the Company incurred shared-based compensation expense related to share options of approximately $52,000.
	For the nine-month period ended September 30, 2014, the Company incurred shared-based compensation expense related to share options and restricted shares of $1,106,000 and $653,000, respectively. For the nine-month period ended September 30, 2013, the Company incurred shared-based compensation expense related to share options of $77,000.
	As of September 30, 2014, there was $4.9 million and $5.2 million of total unrecognized compensation cost related to unvested share options and restricted shares, respectively. These costs are expected to be recognized over weighted-average periods of 2.7 years for share options and 3.5 years for restricted shares.

Note_7_Share_Capital

Note 7 - Share Capital	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	7. Share capital
	In the first nine months of 2014, the Company issued 275,500 restricted shares, as discussed in Note 6. In addition, during the first nine months of 2014, 61,751 ordinary shares were issued upon the exercise of options, and 18,830 ordinary shares were issued upon the exercise of warrants. As of September 30, 2014, there were 40,103,528 ordinary shares authorized and 17,611,348 ordinary shares issued and outstanding.

Note_8_Net_Loss_Per_Share

Note 8 - Net Loss Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	8. Net loss per share
	The following numbers of outstanding ordinary share options, ordinary share warrants and preferred ordinary shares (on an “as converted to ordinary shares” basis) were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive:
		Three months ended September 30,				Nine months ended September 30,
		2014		2013		2014		2013
	Options to purchase ordinary shares		1,168,700		1,306,461		1,197,817		1,306,461
	Ordinary share warrant		—		220,595		—		220,595
	Preferred ordinary shares (as converted)		—		8,267,787		—		8,267,787
	Unvested restricted shares		275,500		—		275,500		—

Note_9_Acquisition

Note 9 - Acquisition	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Business Combination Disclosure [Text Block]	'
	9. Acquisition
	On July 31, 2014 (“date of the acquisition”), the Company acquired substantially all of the assets of Boulder, a privately owned company developing immunology-based assays for rheumatology and infectious diseases. The assets acquired primarily relate to assays for Lyme disease and gout and an assay to help select biologics for autoimmune disease based on monitoring and prognosis of drug response that was acquired in conjunction with the Boulder acquisition. As part of the transaction, Boulder transferred to the Company all shares of capital stock in its wholly-owned subsidiary, Boulder Diagnostics Europe GmbH, such that the Company has become the sole owner of Boulder Diagnostics Europe GmbH.
	The terms of the purchase agreement provided for an upfront payment of $1.7 million and contingent purchase price consideration consisting of future potential milestone payments totaling up to $6.1 million in respect of the Lyme disease and gout assays at any time on or prior to July 31, 2024. The milestone payments consist of up to $400,000 for the completion of studies related to acquired technologies, up to $700,000 for the development of diagnostic test kits, $500,000 for the first patient enrolled in an Institutional Review Board approved study, up to $1.5 million for the issuance of patents, and up to $3.0 million for approvals or clearances by the U.S. Food and Drug Administration. The Company has determined that this liability is a Level 3 fair value measurement within the FASB’s fair value hierarchy and the fair value has been estimated to be $1.2 million on the date of acquisition based on significant assumptions, including the probabilities of milestone occurrence, the expected timing of milestone payments, and a discount rate of 15%. Such liability is adjusted to fair value at each reporting date, with the adjustment reflected in general and administrative expenses. See Note 2 (Fair value measurement) for information pertaining to changes in the fair value of this liability.
	The acquisition of Boulder was accounted for under the acquisition method of accounting and the purchase price allocation was provisionally prepared during the third quarter of 2014. While the Company is close to finalization of the purchase price accounting, it has recorded provisional amounts for all of the assets acquired and the liabilities assumed, based upon their estimated fair values at the date of the business acquisition. These provisional amounts may be adjusted as necessary during the measurement period (up to one year from the acquisition date) while the accounting is finalized. Total consideration was (in thousands):
	Cash consideration	$	1,724
	Estimated fair value of contingent consideration		1,247
	Total consideration transferred	$	2,971
	$183,200 of the cash consideration has been placed in an escrow account for a period of 24 months as security for any undisclosed liabilities and as indemnification for certain items. The Company paid approximately $181,000 in transaction costs associated with this transaction, which is included in general and administrative expense in the statement of operations.
	The following table summarizes the purchase price of the Boulder acquisition, the fair value of identified assets acquired and liabilities assumed at the acquisition date (in thousands):
	Assets acquired:
	Cash	$	8
	Accounts receivable		15
	Inventory		40
	Prepaid expenses and other		12
	Property and equipment		359
	In-process research and development		2,627
	Total assets acquired		3,061
	Liabilities assumed:
	Accounts payable		(97	)
	Accrued liabilities		(14	)
	Other current liabilities		(34	)
	Total liabilities assumed		(145	)
	Net assets acquired		2,916
	Add: goodwill		55
	Total consideration transferred	$	2,971
	On the date of the acquisition the fair value of IPR&D acquired was determined to be $2.6 million ($1.8 million for the Lyme disease assay, $0.5 million for the assay to help select biologics for autoimmune disease based on monitoring and prognosis of drug response that was acquired in conjunction with the Boulder acquisition, and $0.3 million for the gout assay) using the excess earnings method with significant inputs, including estimates of the timing and cost required for product approval, revenue growth, gross margin, operating expenses and a 15% discount rate, that are not observable. We consider the fair value of IPR&D to be a Level 3 fair value asset due to the significant estimates and assumptions used by management in establishing the estimated fair value.
	Goodwill and IPR&D are indefinite-lived intangible assets and are not amortized. Rather, they are reviewed for impairment at least annually. There was no evidence of any impairments at September 30, 2014 and there were no impairment charges during the quarter ended September 30, 2014.
	Actual results of operations of Boulder are included in the unaudited condensed consolidated interim financial statements from the date of the acquisition, including revenues in the amount of $17,000 for the quarter ended September 30, 2014 and losses from operations of $100,000 for the quarter ended September 30, 2014. The functional currency for Boulder in Germany is the Euro.
	Pro Forma Information:The unaudited pro forma condensed consolidated statement of operations of the Company, set forth below, gives effect to the Company’s acquisition of Boulder, using the acquisition method as if it occurred on January 1, 2013. These amounts are not necessarily indicative of the consolidated results of operations for future years or actual results that would have been realized had the acquisition occurred as of the beginning of each such year:
		Pro Forma
		Three months ended September 30,						Nine months ended September 30,
	(in thousands, except share and per share data)	2014			2013			2014			2013
	Total revenues	$	13,335		$	10,772		$	37,459		$	28,663
	Net loss	$	(5,987	)	$	(3,508	)	$	(15,707	)	$	(6,204	)
	Net loss per share—basic and diluted	$	(0.35	)	$	(1.50	)	$	(0.91	)	$	(2.75	)
	Weighted average shares outstanding—basic and diluted	$	17,333,441		$	2,331,990		$	17,300,881		$	2,256,494

Note_2_Fair_Value_Measurement_

Note 2 - Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	'
					Fair value measurements at September 30, 2014 using
	(in thousands)	30-Sep-14			Quoted prices in active markets for identical assets		Significant		Significant
					(Level 1)		other		unobservable
							observable		inputs
							inputs		(Level 3)
							(Level 2)
	Liabilities:
	Contingent purchase price consideration	$	1,234		$	—	$	—	$	1,234
	Total	$	1,234		$	—	$	—	$	1,234
					Fair value measurements at December 31, 2013 using
	(in thousands)	31-Dec-13			Quoted prices in active markets for identical assets		Significant		Significant
					(Level 1)		other		unobservable
							observable		inputs
							inputs		(Level 3)
							(Level 2)
	Liabilities:
	Ordinary share warrants	$	296		$	—	$	—	$	296
	Total	$	296		$	—	$	—	$	296
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	(in thousands)	Three months ended September 30, 2014
	Balance – beginning	$	—
	Contingent purchase price consideration		1,247
	Change in fair value of contingent purchase price consideration		38
	Foreign currency adjustment		(51	)
	Balance at September 30, 2014	$	1,234
	(in thousands)	Nine months ended September 30, 2014
	Balance – beginning	$	296
	Change in fair value of warrant liability		22
	Reclassification of liability to additional paid-in capital upon exercise of warrants		(318	)
	Contingent purchase price consideration		1,247
	Change in fair value of contingent purchase price consideration		38
	Foreign currency adjustment		(51	)
	Balance at September 30, 2014	$	1,234

Note_3_Accounts_Receivable_Net1

Note 3 - Accounts Receivable, Net (Tables)	9 Months Ended
	Sep. 30, 2014
Receivables [Abstract]	'
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	'
	(in thousands)	September 30,			December 31,
		2014			2013
	Accounts receivable	$	5,325		$	4,919
	Less allowance for uncollectible accounts receivable		(114	)		(165	)
	Accounts receivable, net	$	5,211		$	4,754

Note_4_Inventory_Tables

Note 4 - Inventory (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	(in thousands)	September 30,		December 31,
		2014		2013
	Raw materials	$	3,455	$	2,866
	Finished goods		3,060		2,584
	Inventory, net	$	6,515	$	5,450

Note_5_Accrued_Liabilities_Tab

Note 5 - Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	(in thousands)	September 30,		December 31,
		2014		2013
	Employee related expenses	$	3,278	$	2,766
	Royalties		1,390		2,064
	Professional services		433		99
	Rent		256		366
	Inventory		136		293
	Accrued initial public offering costs		—		845
	Other accrued liabilities		684		503
	Total accrued liabilities	$	6,177	$	6,936

Note_6_Share_Option_and_Equity1

Note 6 - Share Option and Equity Incentive Plan (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
		Three months ended September 30,				Nine months ended September 30,
	(in thousands)	2014		2013		2014		2013
	Cost of revenue	$	37	$	1	$	91	$	3
	General and administrative		435		51		1,045		68
	Research and development		20		—		30		—
	Sales and marketing		242		—		593		6
	Total share-based compensation	$	734	$	52	$	1,759	$	77

Note_8_Net_Loss_Per_Share_Tabl

Note 8 - Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		Three months ended September 30,				Nine months ended September 30,
		2014		2013		2014		2013
	Options to purchase ordinary shares		1,168,700		1,306,461		1,197,817		1,306,461
	Ordinary share warrant		—		220,595		—		220,595
	Preferred ordinary shares (as converted)		—		8,267,787		—		8,267,787
	Unvested restricted shares		275,500		—		275,500		—

Note_9_Acquisition_Tables

Note 9 - Acquisition (Tables)	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]	'
	Cash consideration	$	1,724
	Estimated fair value of contingent consideration		1,247
	Total consideration transferred	$	2,971
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	'
	Assets acquired:
	Cash	$	8
	Accounts receivable		15
	Inventory		40
	Prepaid expenses and other		12
	Property and equipment		359
	In-process research and development		2,627
	Total assets acquired		3,061
	Liabilities assumed:
	Accounts payable		(97	)
	Accrued liabilities		(14	)
	Other current liabilities		(34	)
	Total liabilities assumed		(145	)
	Net assets acquired		2,916
	Add: goodwill		55
	Total consideration transferred	$	2,971
Business Acquisition, Pro Forma Information [Table Text Block]	'
		Pro Forma
		Three months ended September 30,						Nine months ended September 30,
	(in thousands, except share and per share data)	2014			2013			2014			2013
	Total revenues	$	13,335		$	10,772		$	37,459		$	28,663
	Net loss	$	(5,987	)	$	(3,508	)	$	(15,707	)	$	(6,204	)
	Net loss per share—basic and diluted	$	(0.35	)	$	(1.50	)	$	(0.91	)	$	(2.75	)
	Weighted average shares outstanding—basic and diluted	$	17,333,441		$	2,331,990		$	17,300,881		$	2,256,494

Note_2_Fair_Value_Measurement_1

Note 2 - Fair Value Measurement (Details) (USD $)	9 Months Ended			1 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	31-May-13	Apr. 30, 2014	Apr. 30, 2014	Dec. 31, 2013	Jul. 31, 2014	31-May-13	31-May-13
				Ordinary Share Warrants [Member]	Ordinary Share Warrants [Member]	Ordinary Share Warrants [Member]	Milestone Payments [Member]	Loan Agreement with Commercial Bank [Member]	Revolving Credit Facility [Member]
							Boulder Diagnostics, Inc. [Member]
Note 2 - Fair Value Measurement (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Debt Instrument, Face Amount	'	'	'	'	'	'	'	$6,000,000	'
Debt Instrument, Additional Borrowing Amount If Certain Revenue Milestones Are Met	'	'	'	'	'	'	'	1,000,000	'
Line of Credit Facility, Maximum Borrowing Capacity	'	'	'	'	'	'	'	'	5,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	'	'	15,791	'	'	'	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	'	'	$0.80	'	'	'	'	'	'
Stock Issued During Period, Shares, Warrant Exercised (in Shares)	18,830	'	'	15,148	'	'	'	'	'
Derivative Liability, Noncurrent	'	296,000	'	'	318,000	296,000	'	'	'
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	'	'	'	'	'	'	$6,100,000	'	'

Note_2_Fair_Value_Measurement_2

Note 2 - Fair Value Measurement (Details) - Liabilities Measured at Fair Value on Recurring Basis (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2013	Apr. 30, 2014	Dec. 31, 2013	Sep. 30, 2014
			Ordinary Share Warrants [Member]	Ordinary Share Warrants [Member]	Ordinary Share Warrants [Member]	Fair Value, Inputs, Level 3 [Member]
			Fair Value, Inputs, Level 3 [Member]
Note 2 - Fair Value Measurement (Details) - Liabilities Measured at Fair Value on Recurring Basis [Line Items]	'	'	'	'	'	'
Contingent purchase price consideration	$1,234,000	'	'	'	'	$1,234,000
Total	1,234,000	'	296,000	'	296,000	1,234,000
Ordinary share warrants	'	$296,000	$296,000	$318,000	$296,000	'

Note_2_Fair_Value_Measurement_3

Note 2 - Fair Value Measurement (Details) - Changes in the Fair Value of the Company's Level 3 Financial Liabilities (USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Balance - beginning	$0	$296
Foreign currency adjustment	-51	-51
Balance at September 30, 2014	1,234	1,234
Contingent Purchase Price Consideration [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Contingent purchase price consideration	1,247	1,247
Change in fair value	38	38
Ordinary Share Warrants [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Change in fair value	'	22
Reclassification of liability to additional paid-in capital upon exercise of warrants	'	($318)

Note_3_Accounts_Receivable_Net2

Note 3 - Accounts Receivable, Net (Details) - Accounts Receivable, Net (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounts Receivable, Net [Abstract]	'	'
Accounts receivable	$5,325	$4,919
Less allowance for uncollectible accounts receivable	-114	-165
Accounts receivable, net	$5,211	$4,754

Note_4_Inventory_Details_Inven

Note 4 - Inventory (Details) - Inventory (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory [Abstract]	'	'
Raw materials	$3,455	$2,866
Finished goods	3,060	2,584
Inventory, net	$6,515	$5,450

Note_5_Accrued_Liabilities_Det

Note 5 - Accrued Liabilities (Details) - Accrued Liabilities (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities [Abstract]	'	'
Employee related expenses	$3,278	$2,766
Royalties	1,390	2,064
Professional services	433	99
Rent	256	366
Inventory	136	293
Accrued initial public offering costs	'	845
Other accrued liabilities	684	503
Total accrued liabilities	$6,177	$6,936

Note_6_Share_Option_and_Equity2

Note 6 - Share Option and Equity Incentive Plan (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Note 6 - Share Option and Equity Incentive Plan (Details) [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	$734,000	$52,000	$1,759,000	$77,000
Employee Stock Option [Member] | The 2013 Plan [Member]	'	'	'	'
Note 6 - Share Option and Equity Incentive Plan (Details) [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	'	'	'10 years	'
Employee Stock Option [Member]	'	'	'	'
Note 6 - Share Option and Equity Incentive Plan (Details) [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	446,000	52,000	1,106,000	77,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	4,900,000	'	4,900,000	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'	'	'2 years 255 days	'
Restricted Stock [Member] | The 2013 Plan [Member]	'	'	'	'
Note 6 - Share Option and Equity Incentive Plan (Details) [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares)	20,800	'	275,500	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)	$13.25	'	$22.25	'
Restricted Stock [Member]	'	'	'	'
Note 6 - Share Option and Equity Incentive Plan (Details) [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	288,000	'	653,000	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$5,200,000	'	$5,200,000	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'	'	'3 years 6 months	'
Second Anniversary of Grant Date [Member] | The 2013 Plan [Member]	'	'	'	'
Note 6 - Share Option and Equity Incentive Plan (Details) [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	'	'	40.00%	'
Third Anniversary of Grant Date [Member] | The 2013 Plan [Member]	'	'	'	'
Note 6 - Share Option and Equity Incentive Plan (Details) [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	'	'	30.00%	'
Fourth Anniversary of Grant Date [Member] | The 2013 Plan [Member]	'	'	'	'
Note 6 - Share Option and Equity Incentive Plan (Details) [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	'	'	30.00%	'
The 2013 Plan [Member]	'	'	'	'
Note 6 - Share Option and Equity Incentive Plan (Details) [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	89,800	'	556,252	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit (in Dollars per share)	$13.25	'	$13.25	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)	$6.28	'	$9.71	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit (in Dollars per share)	'	'	$22.99	'

Note_6_Share_Option_and_Equity3

Note 6 - Share Option and Equity Incentive Plan (Details) - Expense Recognized Related to Share-based Compensation (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Share-based compensation	$734,000	$52,000	$1,759,000	$77,000
Cost of Sales [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Share-based compensation	37,000	1,000	91,000	3,000
General and Administrative Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Share-based compensation	435,000	51,000	1,045,000	68,000
Research and Development Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Share-based compensation	20,000	'	30,000	'
Selling and Marketing Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Share-based compensation	$242,000	'	$593,000	$6,000

Note_7_Share_Capital_Details

Note 7 - Share Capital (Details)	9 Months Ended		3 Months Ended	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014
			Restricted Stock [Member]	Restricted Stock [Member]
			The 2013 Plan [Member]	The 2013 Plan [Member]
Note 7 - Share Capital (Details) [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	'	'	20,800	275,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	61,751	'	'	'
Stock Issued During Period, Shares, Warrant Exercised	18,830	'	'	'
Common Stock, Shares Authorized	40,103,528	25,189,285	'	'
Common Stock, Shares, Issued	17,611,348	17,255,267	'	'
Common Stock, Shares, Outstanding	17,611,348	17,255,267	'	'

Note_8_Net_Loss_Per_Share_Deta

Note 8 - Net Loss Per Share (Details) - Antidilutive Securities	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Equity Option [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities	1,168,700	1,306,461	1,197,817	1,306,461
Warrant [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities	'	220,595	'	220,595
Convertible Preferred Ordinary Shares [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities	'	8,267,787	'	8,267,787
Restricted Stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities	275,500	'	275,500	'

Note_9_Acquisition_Details

Note 9 - Acquisition (Details) (USD $)

0 Months Ended

3 Months Ended

2 Months Ended

0 Months Ended

0 Months Ended

3 Months Ended

Jul. 31, 2014

Sep. 30, 2014

Jul. 31, 2014

Sep. 30, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Sep. 30, 2014

Jul. 31, 2014

General and Administrative Expense [Member]

In Process Research and Development [Member]

In Process Research and Development [Member]

Lyme Disease Assay [Member]

Biologics for Autoimmune Disease Assay [Member]

Gout Assay [Member]

Milestone Payments [Member]

Milestone Payments for Completion of Studies Related to Aquired Technologies [Member]

Milestone Payments for Development of Diagnostic Test Kits [Member]

Milestone Payments for the First Patient Enrolled in an Institutional Review Board Approved Study [Member]

Milestone Payments for Issuance of Patents [Member]

Milestone Payments for Approvals or Clearances by the FDA [Member]

Boulder Diagnostics, Inc. [Member]

Boulder Diagnostics, Inc. [Member]

Boulder Diagnostics, Inc. [Member]

Boulder Diagnostics, Inc. [Member]

Boulder Diagnostics, Inc. [Member]

Boulder Diagnostics, Inc. [Member]

Boulder Diagnostics, Inc. [Member]

Boulder Diagnostics, Inc. [Member]

Boulder Diagnostics, Inc. [Member]

Boulder Diagnostics, Inc. [Member]

Boulder Diagnostics, Inc. [Member]

Boulder Diagnostics, Inc. [Member]

Boulder Diagnostics, Inc. [Member]

Boulder Diagnostics, Inc. [Member]

Boulder Diagnostics, Inc. [Member]

Note 9 - Acquisition (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments to Acquire Businesses, Gross

$1,724,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,700,000

'

'

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

'

'

'

'

'

'

'

'

'

6,100,000

400,000

700,000

500,000

1,500,000

3,000,000

'

'

'

Business Combination, Consideration Transferred, Liabilities Incurred

1,247,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,200,000

'

'

Cash Consideration Held in Escrow

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

183,200

Escrow Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'24 months

'

'

Business Combination, Acquisition Related Costs

'

'

'

181,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets

'

'

2,627,000

'

'

2,600,000

1,800,000

500,000

300,000

'

'

'

'

'

'

'

'

'

Fair Value Inputs, Discount Rate

'

'

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill and Intangible Asset Impairment

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17,000

'

Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$100,000

'

Note_9_Acquisition_Details_Bus

Note 9 - Acquisition (Details) - Business Acquisition (USD $)	0 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014
Business Acquisition [Abstract]	'
Cash consideration	$1,724
Estimated fair value of contingent consideration	1,247
Total consideration transferred	$2,971

Note_9_Acquisition_Details_Ass

Note 9 - Acquisition (Details) - Assets Acquired and Liabilities Assumed (USD $)	Sep. 30, 2014	Jul. 31, 2014
In Thousands, unless otherwise specified
Assets Acquired and Liabilities Assumed [Abstract]	'	'
Cash	'	$8
Accounts receivable	'	15
Inventory	'	40
Prepaid expenses and other	'	12
Property and equipment	'	359
In-process research and development	'	2,627
Total assets acquired	'	3,061
Accounts payable	'	-97
Accrued liabilities	'	-14
Other current liabilities	'	-34
Total liabilities assumed	'	-145
Net assets acquired	'	2,916
Add: goodwill	55	55
Total consideration transferred	'	$2,971

Note_9_Acquisition_Details_Pro

Note 9 - Acquisition (Details) - Pro Forma Information (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Pro Forma Information [Abstract]	'	'	'	'
Total revenues	$13,335	$10,772	$37,459	$28,663
Net loss	($5,987)	($3,508)	($15,707)	($6,204)
Net loss per share—basic and diluted (in Dollars per share)	($0.35)	($1.50)	($0.91)	($2.75)
Weighted average shares outstanding—basic and diluted (in Shares)	17,333,441	2,331,990	17,300,881	2,256,494